Renaissance Technologies LLC purchased a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 271,300 shares of the biotechnology company's stock, valued at approximately $2,097,000. Renaissance Technologies LLC owned 0.55% of REGENXBIO at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in REGENXBIO by 67.0% during the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after acquiring an additional 1,659,206 shares in the last quarter. Norges Bank bought a new position in REGENXBIO during the 4th quarter valued at about $3,474,000. Assenagon Asset Management S.A. boosted its holdings in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after acquiring an additional 296,700 shares during the last quarter. Trexquant Investment LP bought a new position in REGENXBIO during the fourth quarter valued at approximately $1,160,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in REGENXBIO in the 4th quarter worth approximately $1,062,000. 88.08% of the stock is owned by institutional investors.
REGENXBIO Stock Performance
RGNX stock traded up $0.11 during midday trading on Thursday, reaching $9.72. 109,380 shares of the company traded hands, compared to its average volume of 984,713. The firm has a market capitalization of $487.34 million, a price-to-earnings ratio of -1.93 and a beta of 1.26. The business has a 50 day moving average of $7.03 and a 200-day moving average of $8.11. REGENXBIO Inc. has a 52-week low of $5.03 and a 52-week high of $17.52.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.
Analyst Ratings Changes
RGNX has been the topic of several research reports. Royal Bank of Canada reissued an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Finally, HC Wainwright lowered their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.63.
View Our Latest Research Report on REGENXBIO
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
